You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 24 No. 6, June 1971 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (81)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Tricyclic Antidepressants and Monoamine Oxidase Inhibitors

Combination Therapy in the Treatment of Depression

Marc Schuckit, MD; Eli Robins, MD; John Feighner, MD

Arch Gen Psychiatry. 1971;24(6):509-514.


Abstract

The combination of a tricyclic and a monoamine oxidase inhibitor (MAOI) has been reported effective in the treatment of depression but is avoided in this country due to concern over adverse reactions. A review of the case reports on which this concern with morbidity is based reveals no convincing evidence that the antidepressant combination taken in therapeutic doses was responsible for the illness reported. An informal review of 350 outpatients, a record examination of 50 inpatients, and a drug trial with 10 current patients has shown no drug-related morbidity. We conclude that the present evidence does not indicate the combined drug regimen unsafe. A suggestion is made for controlled clinical trials of MAOI-tricyclic antidepressant therapy to evaluate better its clinical effectiveness.



Author Affiliations

St. Louis

From the Department of Psychiatry, Washington University School of Medicine, St. Louis.


Footnotes

Accepted for publication July 28, 1970.

Reprint requests to Department of Psychiatry, Washington University School of MedIcine, 4940 Audubon Ave, St. Louis 63110 (Dr. Robins).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The serotonin syndrome and its treatment
Gillman
J Psychopharmacol 1999;13:100-109.
ABSTRACT  

Lithium Carbonate Addition in Tricyclic Antidepressant--Resistant Unipolar Depression: Correlations With the Neurobiologic Actions of Tricyclic Antidepressant Drugs and Lithium Ion on the Serotonin System
de Montigny et al.
Arch Gen Psychiatry 1983;40:1327-1334.
ABSTRACT  

The Safety and Efficacy of Combined Amitriptyline and Tranylcypromine Antidepressant Treatment: A Controlled Trial
Razani et al.
Arch Gen Psychiatry 1983;40:657-661.
ABSTRACT  

Monoamine Oxidase Inhibitors: A Review of Antidepressant Effectiveness
Quitkin et al.
Arch Gen Psychiatry 1979;36:749-760.
ABSTRACT  

A Comparison of Electroconvulsive Therapy and Combined Phenelzine-Amitriptyline in Refractory Depression
Davidson et al.
Arch Gen Psychiatry 1978;35:639-642.
ABSTRACT  

Combining Tricyclic and Monoamine Oxidase Inhibitor Antidepressants
Spiker and Pugh
Arch Gen Psychiatry 1976;33:828-830.
ABSTRACT  

The Monoamine Oxidase Inhibitor, Phenelzine, in the Treatment of Depressive-Anxiety States: A Controlled Clinical Trial
Robinson et al.
Arch Gen Psychiatry 1973;29:407-413.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1971 American Medical Association. All Rights Reserved.